Overview

Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Assessment of ziprasidone safety and efficacy in the treatment of bipolar and schizoaffective disorders.
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Ziprasidone